ZYME - Zymeworks Inc. Debt to Book Capitalization Ratio

Management at Zymeworks Inc. (ZYME), which develops tumor-fighting therapies via immune activation, is revising its strategy to favor priority projects. This chart reflects the company's price action at 3.45, which aligns with the top management's high expertise in capital preservation and collaboration with pharmaceutical leaders. However, a heavy reliance on the success of a single product and ongoing research costs create certain challenges.

ZYME Zymeworks Inc.: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for Zymeworks Inc (ZYME)

- price and consensus price forecast:

Stock Price Zymeworks Inc.|ZYME - Consensus Target

- market capitalization data:

Market Value Zymeworks Biopharmaceuticals|ZYME - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Zymeworks|ZYME - Company Book Value|Market Value to Book Value Ratio zymeworks.com|ZYME - Company Assets

- debt and liquidity data:

Total Debt to Capital Zymeworks Inc.|ZYME - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Zymeworks Corp|ZYME - Company Cumulative Debt|Debt to Book Value Zymeworks Biopharmaceuticals

Analysis of all company metrics:ZYME, Zymeworks Inc.

Finished products of Zymeworks Biopharmaceuticals

Driven by the Azymetric platform and partnerships with pharmaceutical behemoths, Zymeworks Inc. (ZYME) maintains a strong position in cancer therapy. By analyzing the share of leverage in the firm's balance sheet capitalization, an investor assesses the total debt-to-equity ratio, which determines the business's resilience to shocks. Reducing this ratio minimizes bankruptcy risk, ensuring financial autonomy while scaling proprietary developments.

Competitors of Zymeworks Inc.